Emerging targets in sarcoma: Rising to the challenge of RAS signaling in undifferentiated pleomorphic sarcoma.

about

Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.NF1+/- Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response.

P2860

Q48005435-73F35F3B-FE66-4A5E-B734-4C1E6AA5CB0E Q51840300-C25443F8-F38D-4070-A17E-721CF1BC29A4

P2860

Emerging targets in sarcoma: Rising to the challenge of RAS signaling in undifferentiated pleomorphic sarcoma.

Item

http://www.wikidata.org/entity/Q54239575

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Emerging targets in sarcoma: R ...... rentiated pleomorphic sarcoma.

@en

Emerging targets in sarcoma: R ...... rentiated pleomorphic sarcoma.

@nl

type

Item

label

Emerging targets in sarcoma: R ...... rentiated pleomorphic sarcoma.

@en

Emerging targets in sarcoma: R ...... rentiated pleomorphic sarcoma.

@nl

prefLabel

Emerging targets in sarcoma: R ...... rentiated pleomorphic sarcoma.

@en

Emerging targets in sarcoma: R ...... rentiated pleomorphic sarcoma.

@nl

P1476

Emerging targets in sarcoma: R ...... rentiated pleomorphic sarcoma.

@en

P2093

Rebecca D Dodd

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Ras oncogenes: split personalities

Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas.

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

P304

17-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1002/CNCR.29730

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Rebecca D Dodd

P577

2015-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26479175

http://www.w3.org/2001/XMLSchema#string

Emerging targets in sarcoma: Rising to the challenge of RAS signaling in undifferentiated pleomorphic sarcoma.

about

P2860

P2860

Emerging targets in sarcoma: Rising to the challenge of RAS signaling in undifferentiated pleomorphic sarcoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698